3-乙氧基-4-氟苯硼酸 | 900174-65-4

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯硼酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-乙氧基-4-氟苯硼酸
• 中文别名: 3-乙氧基-4-氟苯基硼酸
• 英文名称: 3-ethoxy-4-fluorophenylboronic acid
• 英文别名: (3-ethoxy-4-fluorophenyl)boronic acid
• CAS: 900174-65-4
• 化学式: C₈H₁₀BFO₃
• 分子量: 183.975
• InChiKey: IGAMLTGCYDPORS-UHFFFAOYSA-N

物化性质

• 沸点：
  328.1±52.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Ethoxy-4-fluorophenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Ethoxy-4-fluorophenylboronic acid
CAS number: 900174-65-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H10BFO3
Molecular weight: 184.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-乙氧基-4-氟苯硼酸 、 4-chloro-7-ethyl-7H-imidazo[4,5-c]pyridazine 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 18.0h， 生成 4-(3-ethoxy-4-fluorophenyl)-7-ethyl-7H-imidazo[4,5-c]pyridazine
  参考文献：
  名称：

  新型功能性亚型选择性GABAA正向变构调节剂（PF-06372865）的设计和鉴定。

  摘要：

  GABAA配体门控离子通道的一系列新型咪唑并哒嗪基亚型选择性正变构调节剂（PAM）的设计，优化和评估。从一组初始命中物中，设计了多个亚系列，并根据结合亲和力和功能活性对其进行了评估。由于难以在所需的功能选择性水平上进行设计，因此进行了基于概率的评估，以将项目的工作重点放在单个子系列上，该子系列提供目标配置文件的可能性最大。这些努力最终导致从该亚系列中鉴定出两个候选物，这些候选物已进行到临床前安全性研究，随后又鉴定了临床候选物PF-06372865。

  DOI：

  10.1021/acs.jmedchem.9b00322
• 作为产物：
  描述：

  4-溴-2-乙氧基-1-氟苯 在 正丁基锂 、 硼酸三甲酯 、 盐酸 、 水 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 4.67h， 以69%的产率得到3-乙氧基-4-氟苯硼酸
  参考文献：
  名称：

  Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

  摘要：

  本发明提供了式(I)或(IV)的新型苯基甘氨酰衍生物：或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中变量W、W1、Y、Z、R7、R8、R9和R11如本文所定义。这些化合物是选择性因子VIIa的抑制剂，可用作药物。

  公开号：

  US20070003539A1

文献信息

• Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
  申请人：Zhang Xiaojun

  公开号：US20070003539A1

  公开（公告）日：2007-01-04

  The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W 1 , Y, Z, R 7 , R 8 , R 9 , and R 11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

  本发明提供了式(I)或(IV)的新型苯基甘氨酰衍生物：或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中变量W、W1、Y、Z、R7、R8、R9和R11如本文所定义。这些化合物是选择性因子VIIa的抑制剂，可用作药物。
• Phenylglycinamide derivatives useful as anticoagulants
  申请人：Zhang Xiaojun

  公开号：US20060166997A1

  公开（公告）日：2006-07-27

  The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

  本发明一般涉及抑制丝氨酸蛋白酶的苯基甘氨酰衍生物。具体而言，本发明涉及新型苯基甘氨酰衍生物及其类似物，其可用作凝血级联反应的丝氨酸蛋白酶酶的选择性抑制剂；例如凝血酶、第VIIa因子、第Xa因子、第XIa因子、第IXa因子和/或血浆激肽。特别是，它涉及到的化合物是第VIIa因子的抑制剂。本发明还涉及包含这些化合物的制药组合物及其使用方法。
• Benzamide factor VIIa inhibitors useful as anticoagulants
  申请人：Bristol-Myers Squibb Company

  公开号：US08222453B2

  公开（公告）日：2012-07-17

  The present invention provides novel benzamide derivatives of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, W, Y, Z, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

  本发明提供一种新的苯甲酰胺衍生物，其化学式为(I)：或其立体异构体、互变异构体、药学上可接受的盐、溶剂化合物或前药，其中变量A、W、Y、Z、R8和R9如本文所定义。这些化合物是选择性因子VIIa抑制剂，可用作药物。
• <i>De novo</i> design of type II topoisomerase inhibitors as potential antimicrobial agents targeting a novel binding region
  作者：Kyle M. Orritt、Lipeng Feng、Juliette F. Newell、Jack N. Sutton、Scott Grossman、Thomas Germe、Lauren R. Abbott、Holly L. Jackson、Benjamin K. L. Bury、Anthony Maxwell、Martin J. McPhillie、Colin W. G. Fishwick

  DOI：10.1039/d2md00049k

  日期：——

  synthesised a novel series of biphenyl-based inhibitors inspired by a published thiophene-based allosteric inhibitor. This series was evaluated in vitro against Escherichia coli DNA gyrase and E. coli topoisomerase IV with the most potent compounds exhibiting IC50 values towards the low micromolar range for DNA gyrase and only ∼2-fold less active against topoisomerase IV. The structure–activity relationships

  据预测，到 2050 年，抗微生物药物耐药性将导致全球每年 1000 万人死亡，死亡人数超过癌症，使世界经济损失 100 万亿美元。显然，解决这个问题的策略是必不可少的，因为细菌进化正在使我们目前的抗生素失效。在已建立的抗菌靶 DNA 促旋酶上发现变构结合位点提供了一种新的药物化学策略。由于该位点与氟喹诺酮结合位点不同，因此尚未记录耐药性。使用计算机分子设计方法，我们设计并合成了一系列新的基于联苯的抑制剂，灵感来自已发表的基于噻吩的变构抑制剂。该系列在体外针对大肠杆菌DNA 促旋酶和大肠杆菌拓扑异构酶 IV 最有效的化合物在 DNA 促旋酶的低微摩尔范围内表现出 IC 50值，而对拓扑异构酶 IV 的活性仅低 2 倍。本文报道的结构-活性关系表明进一步利用这一变构位点的见解，提供了克服发展中的氟喹诺酮耐药性的途径。
• A Convenient, Rapid, Conventional Heating Route to MIDA Boronates
  作者：Andrew McGown、Anthony K. Edmonds、Daniel Guest、Verity L. Holmes、Chris Dadswell、Ramón González-Méndez、Charles A. I. Goodall、Mark C. Bagley、Barnaby W. Greenland、John Spencer

  DOI：10.3390/molecules27165052

  日期：——

  A cheap, conventional, sealed heating reactor proved to be a useful alternative to a microwave reactor in the synthesis of a >20-member MIDA boronate library (MIDA = N-methyliminodiacetic acid). Reaction times were 10 min and work-ups were minimal, saving on energy and solvent usage.

  在合成 >20 元 MIDA 硼酸盐库（MIDA = N-甲基亚氨基二乙酸）中，廉价、传统、密封的加热反应器被证明是微波反应器的有用替代品。反应时间为 10 分钟，后处理最少，节省了能源和溶剂的使用。